BibTex format
@article{Mletzko:2017:10.1080/2162402X.2017.1304337,
author = {Mletzko, S and Pinato, DJ and Robey, RC and Dalla, Pria A and Benson, P and Imami, N and Bower, M},
doi = {10.1080/2162402X.2017.1304337},
journal = {Oncoimmunology},
title = {Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.},
url = {http://dx.doi.org/10.1080/2162402X.2017.1304337},
volume = {6},
year = {2017}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Upregulation of programmed death ligand 1 (PD-L1) is a mechanism of immune escape utilized by a variety of tumors. PD-L1 expression in tumor cells or in the surrounding infiltrate correlates with clinical responsiveness to novel therapies targeting the PD-1/PD-L1 immune checkpoint. In the context of HIV-1 infection, Kaposi's sarcoma (KS) is largely responsive to restoration of immunity following combination antiretroviral therapy (cART), but there is a subset that is not. We hypothesized that this subset of cART-refractory KS may utilize the PD-L1 pathway of immune escape. We found that PD-L1 expressing KS had a denser CD8+ T cell (p = 0.03) and PD-L1 positive macrophage peritumoral infiltrate (p = 0.04) to suggest the involvement of PD-L1 in shaping an immune-tolerogenic microenvironment in cART-refractory KS. The presence of PD-L1 expression in association with immune-infiltrating cells provides rationale for the clinical development PD-1/PD-L1-targeted checkpoint inhibitors in cART-refractory KS.
AU - Mletzko,S
AU - Pinato,DJ
AU - Robey,RC
AU - Dalla,Pria A
AU - Benson,P
AU - Imami,N
AU - Bower,M
DO - 10.1080/2162402X.2017.1304337
PY - 2017///
SN - 2162-4011
TI - Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.
T2 - Oncoimmunology
UR - http://dx.doi.org/10.1080/2162402X.2017.1304337
UR - https://www.ncbi.nlm.nih.gov/pubmed/28919987
VL - 6
ER -